Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients

American Journal of Hypertension

Volumn 13, Issue 6 II SUPPL., 2000, Pages

  Dupuy, O ^a   Bauduceau, B ^a   Mayaudon, H ^a  

^a SERVICE D ENDOCRINOLOGIE   (France)

Author keywords

Hypertension; I1 imidazoline receptor binding; Rilmenidine; Type 2 diabetes

Indexed keywords

CAPTOPRIL; IMIDAZOLINE I1 RECEPTOR; NITRENDIPINE; PLACEBO; RILMENIDINE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING;

EID: 0033926618     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(00)00227-2     Document Type: Article

References (11)

1. Simonson DC: Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988;11:821-827.
2. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH: Prevalence of arterial hypertension in diabetic patients after the JNC-V. Diabetes Care 1994;17:1247-1251.
3. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure. Arch Intern Med 1997;157:2413-2446.
4. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. Br Med J 1998;17:703-713.
5. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-360.
6. Lewis EJ, Hunsincker LG, Pain RP, Rhode RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1562.
7. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650.
8. Mpoy M, Vandeleene B, Ketelslegers JM, Lambert A: Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am J Cardiol 1988; 61:91D-94D.
9. Lubetzki J: Safety and efficacy of rilmenidine in hypertensive type 2 diabetics. Expert report.
10. Luccioni R: Evaluation pharmacoépidémiologique de la rilmenidine chez 18235 hypertendus. Presse Med 1995;24:1857-1864.
11. Bauduceau B, Mayaudon H, Dupuy O: Rilmenidine in the hypertensive type 2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 1999 (in press).